Skip to main content
. Author manuscript; available in PMC: 2015 Dec 2.
Published in final edited form as: Structure. 2014 Nov 13;22(12):1744–1753. doi: 10.1016/j.str.2014.10.001

Figure 1. TLQP-21 binding in 3T3L1 and CHO cells and activity at the C3aR1.

Figure 1

A) Photoactivated crosslinking of a modified TLQP-21 peptide (CL) in CHO and 3T3 cells. CHO membranes were treated with PBS or CL (100 μM). A band of ~56 kDa was observed with anti-TLQP21 in membrane fractions P1and P2 from CL-treated but not PBS-treated membranes. Labeling remained in the protein pellet when P2 membranes were TCA-precipitated (P2 ppt). P2 membranes from 3T3 cells were treated with PBS or increasing concentrations of CL. B) Crosslinking of a modified TLQP-21 peptide (CL) to membranes prepared from 3T3 cells is reduced in the presence of the C3aR1 antagonist SB290157. Lanes 2 and 3 show that crosslinking is not affected by DMSO used to dissolve SB290157. C) The β-arrestin recruitment assay showed that TLQP-21 is an agonist for the human C3aR1, similarly to the human C3a peptide. The mouse TLQP-21 has higher potency than the human TLQP-21.